The continuous evolution of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)presents ongoing challenges and risks to public health,as it renders most reported monoclonal antibodies(mAbs)ineffective due to i...The continuous evolution of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)presents ongoing challenges and risks to public health,as it renders most reported monoclonal antibodies(mAbs)ineffective due to immune escape[1,2].Unlike conventional strategies that rely on conserved epitopes across known viral subtypes,the extraordinary pace and unpredictability of SARS-CoV-2 mutations have progressively eroded these epitopes,thereby destabilizing the foundations of traditional broadly neutralizing antibody(bnAb)development[3].展开更多
基金funded by the External Cooperation Program of CAS(grant number 180GJHZ2023017MI)to G.F.G.
文摘The continuous evolution of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)presents ongoing challenges and risks to public health,as it renders most reported monoclonal antibodies(mAbs)ineffective due to immune escape[1,2].Unlike conventional strategies that rely on conserved epitopes across known viral subtypes,the extraordinary pace and unpredictability of SARS-CoV-2 mutations have progressively eroded these epitopes,thereby destabilizing the foundations of traditional broadly neutralizing antibody(bnAb)development[3].
